Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 34, 2015, Pages E4762-E4771

  Gornalusse, German G ^a,b   Mummidi, Srinivas ^a,b   Gaitan, Alvaro A ^a,b   Jimenez, Fabio ^a,b   Ramsuran, Veron ^c,d   Picton, Anabela ^e,f   Rogers, Kristen ^a,b   Manoharan, Muthu Saravanan ^a,b   Avadhanam, Nymisha ^a,b   Murthy, Krishna K ^g   Martinez, Hernan ^a,b   Murillo, Angela Molano ^a,b   Chykarenko, Zoya A ^h   Hutt, Richard ⁱ   Daskalakis, Demetre ⁱ   Shostakovich Koretskaya, Ludmila ^h   Karim, Salim Abdool ^d   Martin, Jeffrey N ^j,k,l   Deeks, Steven G ^j,k,l   Hecht, Frederick ^j,k,l   Sinclair, Elizabeth ^j,k,l   Clark, Robert A ^a,b   Okulicz, Jason ^m   Valentine, Fred T ⁱ   Martinson, Neil ^f,n,o   Tiemessen, Caroline Tanya ^e,f,n   Ndung'U, Thumbi ^c,d   Hunt, Peter W ^j,k,l   He, Weijing ^a,b   Ahuja, Sunil K ^a,b,p,q   more..

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^h Dnipropetrovsk State Medical Academy   (Ukraine)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l SAN FRANCISCO GENERAL HOSPITAL   (United States)

^m SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

ⁿ SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF WASHINGTON   (United States)

^q ID Consulting   (United States)

more..

Author keywords

CCR5; HIV; Methylation; Polymorphism; T cell activation

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CCR5 PROTEIN, HUMAN; VIRUS RECEPTOR;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; EPITHELIUM CELL; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DNA METHYLATION; EPIGENESIS, GENETIC; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; RECEPTORS, CCR5; RECEPTORS, VIRUS; T-LYMPHOCYTES;

EID: 84940426617     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423228112     Document Type: Article

References (44)

1. Corbeau P, Reynes J (2009) CCR5 antagonism in HIV infection: Ways, effects, and side effects. AIDS 23(15):1931-1943.
2. Paxton WA, et al. (1998) Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of beta-chemokines. Virology 244(1):66-73.
3. Reynes J, Baillat V, Portales P, Clot J, Corbeau P (2003) Low CD4+ T-cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infection. J Acquir Immune Defic Syndr 34(1):114-116.
4. Hladik F, et al. (2005) Combined effect of CCR5-delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 79(18):11677-11684.
5. Catano G, et al. (2011) Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates. J Infect Dis 203(2):263-272.
6. Mummidi S, et al. (2000) Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem 275(25):18946-18961.
7. Gonzalez E, et al. (1999) Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 96(21):12004-12009.
8. Kawamura T, et al. (2003) R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 100(14):8401-8406.
9. Salkowitz JR, et al. (2003) CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol 108(3):234-240.
10. Martin MP, et al. (1998) Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282(5395):1907-1911.
11. Tang J, et al. (2002) Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 76(2):662-672.
12. Kaslow RA, Dorak T, Tang JJ (2005) Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis 191(Suppl 1):S68-S77.
13. Wu L, et al. (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 185(9):1681-1691.
14. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR (1997) The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 94(5):1925-1930.
15. Ostrowski MA, et al. (1998) Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 161(6):3195-3201.
16. Cedar H, Bergman Y (2012) Programming of DNA methylation patterns. Annu Rev Biochem 81:97-117.
17. Lim PS, Shannon MF, Hardy K (2010) Epigenetic control of inducible gene expression in the immune system. Epigenomics 2(6):775-795.
18. Schalkwyk LC, et al. (2010) Allelic skewing of DNA methylation is widespread across the genome. Am J Hum Genet 86(2):196-212.
19. Mummidi S, et al. (2007) Production of specific mRNA transcripts, usage of an alternate promoter, and octamer-binding transcription factors influence the surface expression levels of the HIV coreceptor CCR5 on primary T cells. J Immunol 178(9):5668-5681.
20. Kuipers HF, et al. (2008) CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood 112(5):1610-1619.
21. Rosati M, Valentin A, Patenaude DJ, Pavlakis GN (2001) CCAAT-enhancer-binding protein beta (C/EBP beta) activates CCR5 promoter: Increased C/EBP beta and CCR5 in T lymphocytes from HIV-1-infected individuals. J Immunol 167(3):1654-1662.
22. Heidari N, et al. (2014) Genome-wide map of regulatory interactions in the human genome. Genome Res 24(12):1905-1917.
23. Loetscher P, et al. (1998) CCR5 is characteristic of Th1 lymphocytes. Nature 391(6665): 344-345.
24. Oswald-Richter K, et al. (2007) Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog 3(4):e58.
25. Wierda RJ, et al. (2012) Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors. J Cell Mol Med 16(8):1866-1877.
26. Moon C, et al. (2009) Use of epigenetic modification to induce FOXP3 expression in naïve T cells. Transplant Proc 41(5):1848-1854.
27. Youngblood B, et al. (2011) Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 35(3):400-412.
28. Hunt PW, et al. (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197(1):126-133.
29. Gonzalez E, et al. (2001) Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 98(9):5199-5204.
30. Picton AC, Paximadis M, Tiemessen CT (2010) Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations. Infect Genet Evol 10(4):487-494.
31. Ramsuran V, et al. (2011) Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women. Clin Infect Dis 52(10):1248-1256.
32. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27(3): 406-416.
33. Okulicz JF, et al. (2015) Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med 175(1):88-99.
34. Li Y, et al. (2010) The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol 8(11):e1000533.
35. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72(4):2855-2864.
36. Lin YL, et al. (2002) Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA 99(24):15590-15595.
37. Leung A, Schones DE, Natarajan R (2012) Using epigenetic mechanisms to understand the impact of common disease causing alleles. Curr Opin Immunol 24(5): 558-563.
38. Kim HP, Leonard WJ (2007) CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: A role for DNA methylation. J Exp Med 204(7):1543-1551.
39. Wen AY, Sakamoto KM, Miller LS (2010) The role of the transcription factor CREB in immune function. J Immunol 185(11):6413-6419.
40. Bamshad MJ, et al. (2002) A strong signature of balancing selection in the 5' cisregulatory region of CCR5. Proc Natl Acad Sci USA 99(16):10539-10544.
41. Camargo JF, et al. (2009) CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 182(1):171-182.
42. Portales P, et al. (2012) The intensity of immune activation is linked to the level of CCR5 expression in human immunodeficiency virus type 1-infected persons. Immunology 137(1):89-97.
43. Schröder C, et al. (2007) CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunol 179(4):2289-2299.
44. Gonzalez E, et al. (2005) The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307(5714):1434-1440.